Onasemnogene Abeparvovec Gene Therapy in Presymptomatic spinal muscular atrophy (SMA): SPR1NT study update in children with 3 Copies of SMN2

被引：2

作者：

Strauss, K. ^{[1
]}

Muntoni, F. ^{[2
]}

Farrar, M. ^{[3
]}

Saito, K. ^{[4
]}

Mendell, J. ^{[5
]}

Servais, L. ^{[6
]}

McMillan, H. ^{[7
]}

Swoboda, K. ^{[8
]}

Kwon, J. ^{[9
]}

Zaidman, C. ^{[10
]}

Chiriboga, C. ^{[11
]}

Iannaccone, S. ^{[12
]}

Krueger, J. ^{[13
]}

Parsons, J. ^{[14
]}

Shieh, P. ^{[15
]}

Kavanagh, S. ^{[16
]}

Chand, D. ^{[16
]}

Tauscher-Wisniewski, S. ^{[16
]}

Macek, T. ^{[16
]}

机构：

[1] Clin Special Children, Strasburg, PA USA

[2] UCL, London, England

[3] Sydney Childrens Hosp Network, Randwick, NSW, Australia

[4] Tokyo Womens Med Univ, Tokyo, Japan

[5] Nationwide Childrens Hosp, Columbus, OH USA

[6] MDUK Oxford Neuromuscular Ctr, Oxford, England

[7] Childrens Hosp Eastern Ontario, Ottawa, ON, Canada

[8] Massachusetts Gen Hosp, Boston, MA 02114 USA

[9] Univ WI, Sch Med & Publ Hlth, Madison, WI USA

[10] Washington Univ, Sch Med, St Louis, MO USA

[11] Columbia Univ, Med Ctr, New York, NY USA

[12] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA

[13] Helen DeVos Childrens Hosp, Grand Rapids, MI USA

[14] Univ Colorado, Sch Med, Aurora, CO USA

[15] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

[16] Novartis Gene Therapies, Bannockburn, IL USA

来源：

NEUROMUSCULAR DISORDERS | 2021年 / 31卷

关键词：

D O I：

10.1016/j.nmd.2021.07.299

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

EP.274

引用

页码：S133 / S133

页数：1

共 50 条

[31] Long-term follow-up (LTFU) of onasemnogene abeparvovec gene therapy in spinal muscular atrophy (SMA)
Mendell, J.
Finkel, R.
Mercuri, E.
Strauss, K.
Day, J.
Kleyn, A.
Chand, D.
Tauscher-Wisniewski, S.
Meriggioli, M.
NEUROMUSCULAR DISORDERS, 2021, 31 : S132 - S133
[32] Long-term Follow-up (LTFU) of Onasemnogene Abeparvovec Gene Therapy in Spinal Muscular Atrophy (SMA)
Day, J.
Mendell, J.
Finkel, R.
Mercuri, E.
Strauss, K.
Kleyn, A.
Chand, D.
Tauscher-Wisniewski, S.
Meriggioli, M.
ANNALS OF NEUROLOGY, 2021, 90 : S151 - S152
[33] Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial
Day, John W.
Finkel, Richard S.
Chiriboga, Claudia A.
Connolly, Anne M.
Crawford, Thomas O.
Darras, Basil T.
Iannaccone, Susan T.
Kuntz, Nancy L.
Pena, Loren D. M.
Shieh, Perry B.
Smith, Edward C.
Kwon, Jennifer M.
Zaidman, Craig M.
Schultz, Meredith
Feltner, Douglas E.
Tauscher-Wisniewski, Sitra
Ouyang, Haojun
Chand, Deepa H.
Sproule, Douglas M.
Macek, Thomas A.
Mendell, Jerry R.
LANCET NEUROLOGY, 2021, 20 (04): : 284 - 293
[34] Long-Term Follow-Up (LTFU) of Onasemnogene Abeparvovec Gene Therapy in Spinal Muscular Atrophy (SMA)
Mendell, Jerry
Finkel, Richard
Mercuri, Eugenio
Strauss, Kevin
Day, John
Kleyn, Aaron
Chand, Deepa
Tauscher-Wisniewski, Sitra
Meriggioli, Matthew
NEUROLOGY, 2021, 96 (15)
[35] ONASEMNOGENE ABEPARVOVEC GENE THERAPY FOR SPINAL MUSCULAR ATROPHY TYPE 1: PHASE 3 STUDY (STR1VE-US)
Day, J. W.
Finkel, R. S.
Connolly, A. M.
Darras, B. T.
Iannaccone, S. T.
Kuntz, N. L.
Pena, L. D. M.
Smith, E. C.
Chiriboga, C. A.
Crawford, T. O.
Shieh, P. B.
Kwon, J. M.
Zaidman, C. M.
Schultz, M.
Kausar, I.
Chand, D.
Tauscher-Wisniewski, S.
Ouyang, H.
Macek, T. A.
Mendell, J. R.
THORAX, 2021, 76 : A10 - A11
[36] Long-term follow-up of onasemnogene abeparvovec gene therapy in patients with spinal muscular atrophy (SMA) type 1
Mendell, J.
Wigderson, M.
Alecu, I.
Yang, L.
Mehl, L.
Connolly, A.
NEUROMUSCULAR DISORDERS, 2023, 33 : S91 - S91
[37] Long-term follow-up of onasemnogene abeparvovec gene therapy in spinal muscular atrophy type 1 (SMA1)
Mendell, J.
Shell, R.
Lehman, K.
McColly, M.
Lowes, L.
Alfano, L.
Miller, N.
Iammarino, M.
Church, K.
Ogrinc, F.
Ouyang, H.
Kernbauer, E.
Joshi, S.
Sproule, D.
Meriggioli, M.
Feltner, D.
Al-Zaidy, S.
NEUROMUSCULAR DISORDERS, 2020, 30 : S122 - S123
[38] Onasemnogene Abeparvovec-xioi Gene-Replacement Therapy for Spinal Muscular Atrophy Type 1 (SMA1): Phase 3 US Study (STR1VE) Update
Day, John W.
Chiriboga, Claudia A.
Crawford, Thomas O.
Darras, Basil T.
Finkel, Richard S.
Connolly, Anne M.
Iannaccone, Susan T.
Kuntz, Nancy L.
Pena, Loren D. M.
Shieh, Perry B.
Smith, Edward C.
Schultz, Meredith
Feltner, Douglas E.
Tauscher-Wisniewski, Sitra
Ogrinc, Francis G.
Shah, Ankita
Ouyang, Haojun
Macek, Thomas
Kernbauer, Elaine
Sproule, Douglas M.
Mendell, Jerry R.
NEUROLOGY, 2020, 94 (15)
[39] Patients with spinal muscular atrophy (SMA) and healthy siblings sharing homozygous deletions of the SMN1 gene reveal an identical number of SMN2 gene copies but different SMN protein levels
Lemmink, H. H.
Vos, Y. J.
Plaza de Menacho, I.
Dijkhuis, J.
Knoers, N. V. A. M.
de Visser, M.
Buys, C. H. C. M.
NEUROMUSCULAR DISORDERS, 2006, 16 (9-10) : 652 - 652
[40] Intravenous and Intrathecal Onasemnogene Abeparvovec Gene Therapy in Symptomatic and Presymptomatic Spinal Muscular Atrophy: Long-Term Follow-Up Study
Darras, Basil
Mercuri, Eugenio
Strauss, Kevin
Day, John
Chien, Yin-Hsiu
Masson, Ricardo
Wigderson, Melissa
Alecu, Iulian
Ballarini, Nicolas
Mehl, Lesa
Marra, Jonathan
Connolly, Anne
NEUROLOGY, 2023, 100 (17)

← 1 2 3 4 5 →